Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GERN's Cash to Debt is ranked higher than
99% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. GERN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GERN' s Cash to Debt Range Over the Past 10 Years
Min: 0.87  Med: 1855.26 Max: No Debt
Current: No Debt
Equity to Asset 0.95
GERN's Equity to Asset is ranked higher than
94% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GERN: 0.95 )
Ranked among companies with meaningful Equity to Asset only.
GERN' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.90 Max: 0.97
Current: 0.95
0.37
0.97
F-Score: 5
Z-Score: 30.08
M-Score: 24.15
WACC vs ROIC
26.32%
-2.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.49
GERN's Operating margin (%) is ranked higher than
69% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. GERN: -0.49 )
Ranked among companies with meaningful Operating margin (%) only.
GERN' s Operating margin (%) Range Over the Past 10 Years
Min: -4069.18  Med: -2842.68 Max: -1.54
Current: -0.49
-4069.18
-1.54
Net-margin (%) 1.42
GERN's Net-margin (%) is ranked higher than
71% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. GERN: 1.42 )
Ranked among companies with meaningful Net-margin (%) only.
GERN' s Net-margin (%) Range Over the Past 10 Years
Min: -4066.28  Med: -2767.01 Max: 0.13
Current: 1.42
-4066.28
0.13
ROE (%) 0.39
GERN's ROE (%) is ranked higher than
76% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. GERN: 0.39 )
Ranked among companies with meaningful ROE (%) only.
GERN' s ROE (%) Range Over the Past 10 Years
Min: -60.98  Med: -39.36 Max: 0.03
Current: 0.39
-60.98
0.03
ROA (%) 0.34
GERN's ROA (%) is ranked higher than
77% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. GERN: 0.34 )
Ranked among companies with meaningful ROA (%) only.
GERN' s ROA (%) Range Over the Past 10 Years
Min: -53.81  Med: -35.38 Max: 0.03
Current: 0.34
-53.81
0.03
ROC (Joel Greenblatt) (%) 326.84
GERN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. GERN: 326.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GERN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -26858.87  Med: -2540.58 Max: 70.53
Current: 326.84
-26858.87
70.53
Revenue Growth (3Y)(%) 120.10
GERN's Revenue Growth (3Y)(%) is ranked higher than
96% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. GERN: 120.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GERN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.9  Med: -26.30 Max: 120.1
Current: 120.1
-53.9
120.1
EPS Growth (3Y)(%) -100.00
GERN's EPS Growth (3Y)(%) is ranked lower than
99% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. GERN: -100.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GERN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -12.30 Max: 24
Current: -100
-100
24
» GERN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

GERN Guru Trades in Q2 2015

Jim Simons 1,505,880 sh (+4.93%)
Paul Tudor Jones 17,568 sh (-75.51%)
First Eagle Investment 164,700 sh (-77.40%)
» More
Q3 2015

GERN Guru Trades in Q3 2015

First Eagle Investment 164,700 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 15,777 sh (-10.19%)
» More
Q4 2015

GERN Guru Trades in Q4 2015

Joel Greenblatt 299,986 sh (New)
First Eagle Investment 159,700 sh (-3.04%)
Paul Tudor Jones 14,543 sh (-7.82%)
» More
Q1 2016

GERN Guru Trades in Q1 2016

Jim Simons 453,480 sh (New)
Paul Tudor Jones 104,800 sh (+620.62%)
Joel Greenblatt 466,859 sh (+55.63%)
First Eagle Investment 159,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PTCHF, NAS:MYOK, NAS:ACRS, NAS:PGNX, NAS:ENTA, NAS:OMER, NAS:MNKD, NAS:AGEN, NAS:AMRN, NAS:ARNA, NAS:SGMO, NAS:TLGT, NAS:OTIC, OTCPK:ZLDPF, NAS:XNPT, NAS:SPPI, NAS:CYTK, NAS:RVNC, NAS:CTMX, NAS:NDRM » details
Traded in other countries:GON.Germany,
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.

Geron Corp was incorporated in the State of Delaware on November 28, 1990. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in the segment of the discovery and development of therapeutic products for oncology. It owns commercial rights with U.S. patent coverage extending through 2025 for imetelstat. Its patent rights relating to telomerase cover the cloned genes that encode the RNA component and the catalytic protein component of human telomerase, cells that are immortalized by expression of recombinant hTERT, and cancer diagnostics based on detecting the expression of telomerase in cancer cells. The Company is subject to various and often changing federal, state, local and international laws, rules, regulations, guidelines and recommendations relating to safe working conditions and manufacturing practices.

Ratios

vs
industry
vs
history
P/B 3.22
GERN's P/B is ranked higher than
53% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. GERN: 3.22 )
Ranked among companies with meaningful P/B only.
GERN' s P/B Range Over the Past 10 Years
Min: 1.07  Med: 2.71 Max: 12.12
Current: 3.22
1.07
12.12
P/S 12.21
GERN's P/S is ranked higher than
52% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. GERN: 12.21 )
Ranked among companies with meaningful P/S only.
GERN' s P/S Range Over the Past 10 Years
Min: 11.3  Med: 130.00 Max: 1014.44
Current: 12.21
11.3
1014.44
EV-to-EBIT 542.22
GERN's EV-to-EBIT is ranked lower than
98% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. GERN: 542.22 )
Ranked among companies with meaningful EV-to-EBIT only.
GERN' s EV-to-EBIT Range Over the Past 10 Years
Min: -1775.3  Med: -4.70 Max: 5293.3
Current: 542.22
-1775.3
5293.3
EV-to-EBITDA 487.38
GERN's EV-to-EBITDA is ranked lower than
99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. GERN: 487.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
GERN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2063.2  Med: -4.80 Max: 3733.2
Current: 487.38
-2063.2
3733.2
Current Ratio 16.66
GERN's Current Ratio is ranked higher than
88% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. GERN: 16.66 )
Ranked among companies with meaningful Current Ratio only.
GERN' s Current Ratio Range Over the Past 10 Years
Min: 3.19  Med: 10.04 Max: 33.57
Current: 16.66
3.19
33.57
Quick Ratio 16.66
GERN's Quick Ratio is ranked higher than
88% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. GERN: 16.66 )
Ranked among companies with meaningful Quick Ratio only.
GERN' s Quick Ratio Range Over the Past 10 Years
Min: 3.19  Med: 10.04 Max: 33.57
Current: 16.66
3.19
33.57
Days Sales Outstanding 6.23
GERN's Days Sales Outstanding is ranked higher than
91% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. GERN: 6.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
GERN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.1  Med: 150.84 Max: 304.85
Current: 6.23
12.1
304.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.23
GERN's Price/Net Cash is ranked higher than
60% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. GERN: 4.23 )
Ranked among companies with meaningful Price/Net Cash only.
GERN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.45  Med: 4.01 Max: 223.42
Current: 4.23
1.45
223.42
Price/Net Current Asset Value 4.17
GERN's Price/Net Current Asset Value is ranked higher than
57% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. GERN: 4.17 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GERN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.39  Med: 3.69 Max: 116.57
Current: 4.17
1.39
116.57
Price/Tangible Book 3.20
GERN's Price/Tangible Book is ranked higher than
60% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. GERN: 3.20 )
Ranked among companies with meaningful Price/Tangible Book only.
GERN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 3.15 Max: 19.03
Current: 3.2
1.26
19.03
Price/Median PS Value 0.09
GERN's Price/Median PS Value is ranked higher than
98% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. GERN: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
GERN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.65 Max: 6.96
Current: 0.09
0.05
6.96
Earnings Yield (Greenblatt) (%) 0.19
GERN's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. GERN: 0.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GERN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.20 Max: 0.2
Current: 0.19
0.1
0.2

More Statistics

Revenue (TTM) (Mil) $36.58
Beta3.30
Short Percentage of Float20.82%
52-Week Range $2.30 - 5.30
Shares Outstanding (Mil)158.96

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16
Revenue (Mil $)
EPS ($) -0.25
EPS w/o NRI ($) -0.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:GERN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
Geron Announces Conference Call to Discuss Second Quarter 2016 Financial Results Jul 27 2016
Geron Announces Conference Call to Discuss Second Quarter 2016 Financial Results Jul 27 2016
GERON CORP Files SEC form 8-K, Other Events Jul 25 2016
ETF’s with exposure to Geron Corp. : July 20, 2016 Jul 20 2016
Biotech Equities Technical Briefing on Array BioPharma, Geron, Emergent BioSolutions, and Global... Jul 18 2016
Geron (GERN) Gets Three Patents for Imetelstat in the U.S. Jul 14 2016
Geron Announces Issuance of U.S. Patents Related to Imetelstat Jul 13 2016
Geron Announces Issuance of U.S. Patents Related to Imetelstat Jul 13 2016
ETF’s with exposure to Geron Corp. : June 20, 2016 Jun 20 2016
ETF’s with exposure to Geron Corp. : June 6, 2016 Jun 06 2016
Geron Corp. breached its 50 day moving average in a Bullish Manner : GERN-US : June 2, 2016 Jun 02 2016
GERON CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 19 2016
ETF’s with exposure to Geron Corp. : May 19, 2016 May 18 2016
Geron Corp. :GERN-US: Earnings Analysis: Q1, 2016 By the Numbers May 16 2016
GERON CORP Financials May 13 2016
Actinium Pharmaceuticals Remains Significantly Undervalued May 10 2016
Can Geron Shares Still Ultimately Double? May 08 2016
Edited Transcript of GERN earnings conference call or presentation 5-May-16 8:30pm GMT May 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)